301230 Stock Overview
Operates as a CRO, CDMO, and CMO service provider of drug discovery in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
PharmaResources (Shanghai) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.71 |
| 52 Week High | CN¥44.23 |
| 52 Week Low | CN¥16.28 |
| Beta | 0 |
| 11 Month Change | -7.25% |
| 3 Month Change | -21.50% |
| 1 Year Change | -33.40% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.32% |
Recent News & Updates
PharmaResources (Shanghai) (SZSE:301230) Posted Weak Earnings But There Is More To Worry About
May 02
Shareholder Returns
| 301230 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 0.8% | -5.0% | -1.4% |
| 1Y | -33.4% | -40.2% | -19.1% |
Return vs Industry: 301230 exceeded the CN Life Sciences industry which returned -40.2% over the past year.
Return vs Market: 301230 underperformed the CN Market which returned -19.1% over the past year.
Price Volatility
| 301230 volatility | |
|---|---|
| 301230 Average Weekly Movement | 10.8% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 301230's share price has been volatile over the past 3 months.
Volatility Over Time: 301230's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,047 | Ping Chen | www.pharmaresources.cn |
PharmaResources (Shanghai) Co., Ltd. operates as a CRO, CDMO, and CMO service provider of drug discovery in China. It also manufactures APIs and key intermediates. The company offers preclinical services.
PharmaResources (Shanghai) Co., Ltd. Fundamentals Summary
| 301230 fundamental statistics | |
|---|---|
| Market cap | CN¥3.01b |
| Earnings (TTM) | CN¥26.01m |
| Revenue (TTM) | CN¥499.05m |
121.2x
P/E Ratio6.3x
P/S RatioIs 301230 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301230 income statement (TTM) | |
|---|---|
| Revenue | CN¥499.05m |
| Cost of Revenue | CN¥376.47m |
| Gross Profit | CN¥122.58m |
| Other Expenses | CN¥96.57m |
| Earnings | CN¥26.01m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 24.56% |
| Net Profit Margin | 5.21% |
| Debt/Equity Ratio | 2.1% |
How did 301230 perform over the long term?
See historical performance and comparison